B-1344

N/A

Report date: 2026/02/28 20:00:37

Base Information

Drug NameB-1344
Drug Alias NamePEG-rhmFGF21聚乙二醇化重组人成纤维细胞生长因子21突变体B-1344
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionFibroblast growth factor 21 replacements
TargetsFibroblast growth factor 21
Therapy Area/IndicationsDiabetes Mellitus, Type 2Metabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTasly Biomedical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesTasly Biopharmaceuticals Co LtdTasly Biomedical Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2Metabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A